CN110115295A - One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method - Google Patents
One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method Download PDFInfo
- Publication number
- CN110115295A CN110115295A CN201910329778.XA CN201910329778A CN110115295A CN 110115295 A CN110115295 A CN 110115295A CN 201910329778 A CN201910329778 A CN 201910329778A CN 110115295 A CN110115295 A CN 110115295A
- Authority
- CN
- China
- Prior art keywords
- dha
- milk powder
- ala
- rich
- formula milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 90
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 44
- 241000024188 Andala Species 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000005406 washing Methods 0.000 claims abstract description 24
- 239000003094 microcapsule Substances 0.000 claims abstract description 20
- 238000012545 processing Methods 0.000 claims abstract description 13
- 235000015097 nutrients Nutrition 0.000 claims abstract description 10
- 239000005862 Whey Substances 0.000 claims abstract description 9
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 9
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004519 grease Substances 0.000 claims abstract description 8
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 8
- 239000000944 linseed oil Substances 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims abstract description 8
- 235000019198 oils Nutrition 0.000 claims abstract description 8
- 241000195493 Cryptophyta Species 0.000 claims abstract description 7
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 7
- 239000002540 palm oil Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 16
- 102000011632 Caseins Human genes 0.000 claims description 8
- 108010076119 Caseins Proteins 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 235000019742 Vitamins premix Nutrition 0.000 claims description 4
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000013925 ferrous lactate Nutrition 0.000 claims description 4
- 239000004225 ferrous lactate Substances 0.000 claims description 4
- 229940037907 ferrous lactate Drugs 0.000 claims description 4
- 238000005243 fluidization Methods 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- 229940050168 zinc lactate Drugs 0.000 claims description 4
- 235000000193 zinc lactate Nutrition 0.000 claims description 4
- 239000011576 zinc lactate Substances 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- 235000021247 β-casein Nutrition 0.000 claims description 4
- 239000011552 falling film Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 235000013336 milk Nutrition 0.000 abstract description 15
- 239000008267 milk Substances 0.000 abstract description 15
- 210000004080 milk Anatomy 0.000 abstract description 15
- 239000004615 ingredient Substances 0.000 abstract description 6
- 230000008859 change Effects 0.000 abstract description 4
- 235000013365 dairy product Nutrition 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 239000008158 vegetable oil Substances 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 62
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 46
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 33
- 229940090949 docosahexaenoic acid Drugs 0.000 description 31
- 239000000194 fatty acid Substances 0.000 description 26
- 235000021342 arachidonic acid Nutrition 0.000 description 23
- 229940114079 arachidonic acid Drugs 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 150000004665 fatty acids Chemical class 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 206010039966 Senile dementia Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 5
- 229940033080 omega-6 fatty acid Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006386 memory function Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 108700028909 Serum Amyloid A Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 2
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000004499 emulsifiable powder Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009931 pascalization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, belongs to technical field of processing dairy products.It is comprised the following steps that: 1) taking pure water, skimmed milk powder, desalted whey powder and the mixing of microcapsules carburetion, newborn original washing powder is made using wet processing, the microcapsules carburetion is extracted DHA, ARA grease by palm oil, linseed oil, algae oil and obtained by microencapsulation；2) the newborn original washing powder for taking step 1) to obtain is dry-mixed with nutrient, obtains rich in DHA, AA and ALA Quinquagenarian formula milk powder.Present invention application skimmed milk power, the principal ingredients of whey powder, vegetable oil as Quinquagenarian formula milk powder, for stability ingredient and heat-sensitive ingredients, the processing technology combined using wet-dry change, makes that the uniformity of milk powder finished product is high, instant effect is good, stability is more excellent, and proposes the formula of optimization.
Description
Technical field
The invention belongs to technical field of processing dairy products, and in particular to one kind is rich in DHA, AA and ALA person in middle and old age formula milk
Powder, preparation method thereof.
Background technique
Aging of population is one of Social Events of 21 century.Senile A Ercihai Summerside disease (Alzheimer '
Sdisease, AD) it is worldwide common complaint among the elderly, the 4th of human death's reason is accounted for, is by the europathology of Germany
Scholar A Ercihai Summerside (Alois Alzheimer) is in first discovery in 1907, and with its naming.A Ercihai Summerside disease is
A kind of diffusivity nervous centralis degenerative disease, clinical manifestation are intelligence and cognition dysfunction.A Ercihai Summerside disease
The cause of disease and pathogenesis it is still not fully aware of, there is abundant evidence that in brain tissue amyloid A β 1-42 accumulation be to cause
The arch-criminal of A Ercihai Summerside disease, but the formation mechenism of amyloid A β 1-42 and pathogenesis be not also fully aware of.It is reported that
In over-65s elderly population, the dull-witted rate of falling ill accounts for the 4%-7% of total population, reachable in 80 years old or more elderly population
20%, until 2015, China's elderly population will be more than 200,000,000, and later period 1940's can be more than 400,000,000.With mankind's aging
The arrival of society, senile dementia disease (A Ercihai Summerside disease) have become global problem.Senile dementia or senile Ah
Er Cihai Summerside sick (Alzheimer ' s disease, AD) is a kind of diffusivity nervous centralis degenerative disease, is recognized with progressive
Obstacle, intelelectual deterioration and personality change are characterized, with cerebral amyloid A β 1-42 deposition, neurofibrillary tangles, nerve
Member is lost and slow inflammatory pathologies.The cause of disease and pathogenesis of AD be not still fully aware of, clinically can behave as into
Row impaired memory function, cognitive function disorder and behavioral aspect change.Especially AD lacks objective efficiency index before death.City at present
The drug for the treatment of senile dementia on face does not reach highly satisfactory result also.
Unsaturated fatty acid docosahexaenoic acid (DHA) and arachidonic acid (AA) are essential fatty acids, respectively
It is generally acknowledged brain nutrition substance for 6 fatty acid of ω and omega-3 fatty acid, the development of Central nervous system is especially important, this two
Kind of unsaturated fatty acid cannot synthesize in vivo or synthetic quantity can not meet the needs of body, and some researches show that 3 fat of ω at present
The eurythmy of acid and 6 fatty acid of ω facilitates memory function.A large amount of clinical tests prove that omega-fatty acid is to big in recent years
The protection of cranial nerve and Function play good facilitation.Omega-fatty acid is rouge of the double bond in carbochain antepenulatimate
Fat acid general name includes the members such as alpha-linolenic acid, EPA, DHA, and through animal or clinical proof, these fatty acid have cranial nerve good
Good protection and facilitation.Fedorva etc. (2009) lacks the food of omega-fatty acid to mouse feeding, after death surveys to mouse
Monoamine transmitter level and its metabolite content in its fixed brain different parts.The result shows that feeding lacks omega-fatty acid
Dopamine and serotonin are all changed in the mouse midbrain rim path of food and cortex path, and this are changed
It is relevant to become the behavior damage being likely to mouse.It is tested and is found by not grace water maze, feeding lacks omega-fatty acid food
Mouse the position of escape opening must can be just found with more times.And the position of escape opening ought be become original position
When the opposite direction set, the mouse that feeding lacks omega-fatty acid still presses original direction escape, hence it is evident that lacks flexible adapt to
Ability, it is seen that omega-fatty acid enables to mouse to be improved in action learning.Kim etc. (2008) is sent out by numerous studies
This effect of existing Raf-1 kinases and DHA have close association: being on the one hand the accumulation due to phosphatidylserine, another party
Face is also related with the largely accumulation of DHA in cell membrane.However the shortage of phosphatidylserine and DHA all can be to Raf-1 kinases
Activation adversely affects.Lim etc. (2005) intervenes the mouse of 2 d of rigid birth, to mouse difference feeding by oleic acid+l%
DHA, oleic acid+l% EPA and oleic acid composition artificial dairy products, the DHA and learning ability of its brain are carried out when mouse adult
Analysis finds that mouse brain DHA content of the DHA than feeding oleic acid+1%DPA of the mouse brain of feeding oleic acid+1%DHA is higher by
63%~65%, and its incubation period of escaping of the mouse of grace water maze test discovery brain shortage DHA is not longer.Freund—Levi
The patient for suffering from senile dementia to 174 Deng (2006) is carried out at pretreatment, and discovery omega-fatty acid, which can slightly reduce, to be suffered from
Spend the decrease speed of senile dementia patients cognitive ability.
Milk powder is the optimum carrier for preparing prevention senile dementia diet, and the constitution decline of the elderly, masticatory ability is weak, digestion
The deterioration of organ, needs food easy to digest full of nutrition, and milk powder is undoubtedly supplemented the nutrients at many elderlys, kept
The excellent selection of health.Nevertheless, the specific nutrition supplement that suitable the elderly selects currently on the market, maintaining healthy is special
Function formula milk product category is not enriched still, by taking diabetic as an example (middle-aged and the old is in the majority), meets the low of their demands
Sugar, low fat food be even more rareness, old milk powder is very few, and prevent senile dementia functional formulas milk powder market at present
Still belong to blank.A Government Report that in September, 2016 is announced points out that commodity relevant to the elderly and service account for Consumption of China knot
The 8% of structure, this 4,000,000,000,000 RMB of market value, it means that the old people food market of hundreds of millions ranks awaits development.
In conclusion in this context, the present invention covers grease peculiar smell using microcapsules technology, new skill is processed in conjunction with milk powder
Art, rational allocation omega-fatty acid DHA, ALA and ω -6 fatty acid AA ratio develop auxiliary unsaturated fatty acid nutrition arrangement
Help the prescription emulsifiable powder of senile memory.
Summary of the invention
In view of the problems of the existing technology, it is an object of the invention to design to provide a kind of be rich in DHA, AA and ALA
The technical solution of geriatric formulas method for preparing milk, the geriatric formulas milk powder change omega-fatty acid DHA, ALA and ω -6 rouge
Fat acid AA ratio nutrition composition, there is the biological function nutrition of highly significant, is inhaled by conjunction with milk powder product, being conducive to digestion
It receives and metabolic effects enhances, particularly suitable for person in middle and old age group etc..
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that including following work
Skill step:
1) pure water, skimmed milk powder, desalted whey powder and the mixing of microcapsules carburetion are taken, newborn original washing powder, institute are made using wet processing
The microcapsules carburetion stated is extracted DHA, ARA grease by palm oil, linseed oil, algae oil and is obtained by microencapsulation；
2) the newborn original washing powder for taking step 1) to obtain is dry-mixed with nutrient, obtains rich in DHA, AA and ALA Quinquagenarian formula milk powder.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the step
1) taken in 500~700 parts of pure water, 100~300 parts of skimmed milk powder, 60~100 parts of desalted whey powder and microcapsules carburetion 10~
40 parts of mixing.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the step
1) microcapsules carburetion is made by the raw material of following mass percent by microencapsulation in: palm oil 70~90%, linseed oil 2
~12%, the ARA grease 5~15% that the algae oil that concentration is 35~45% extracts DHA2~5%, concentration is 40~45%.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the step
1) wet processing specifically includes high-pressure homogeneous, reduced pressure, spray drying and fluidisation cooling in.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the step
2) newborn original washing powder and nutrient are dry-mixed in specifically: the newborn sealed Pipeline transport of original washing powder to mixing machine, in the following proportions by newborn original washing powder
It is mixed with nutrient: newborn original washing powder 1000kg, 0.5~1.0kg of galactooligosaccharide, 0.5~1.0kg of taurine, L-carnitine winestone
0.5~1.0kg of hydrochlorate, 0.5~1.0kg of ferrous lactate, 0.5~1.0kg of beta carotene, zinc lactate 0.5~1.0kg, L- are anti-
Bad hematic acid sodium 0.5~1.0kg, 2~3kg of vitamin premix.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that micro- glue
Encapsulated technique are as follows: using casein mixture as wall material, it is 70% that wherein beta-casein, which accounts for mass ratio, and solid-liquid ratio 4:1 is cut
Emulsification and homogeneous are cut, wherein for emulsification pretreatment condition are as follows: 45 ± 5 DEG C of temperature holding, revolving speed setting 8000rpm operation 10~
15min, processing condition are as follows: 25~40Mpa of pressure.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the high pressure
Processing condition are as follows: 25~40Mpa of pressure.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the decompression
Concentration condition are as follows: temperature is kept for 55 ± 5 DEG C, and vacuum degree is set as 0.03~0.06Mpa, is concentrated into dry using two effect falling film types
Matter content is 35~40%, the material after reduced pressure, is pumped into storage container and is warming up to 60~75 DEG C, keeps the temperature 5~25 minutes.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that described is sprayed
Drying condition are as follows: temperature of charge is kept for 60~75 DEG C, 160 DEG C of inlet air temperature, 75~90 DEG C of leaving air temp.
Described one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that the fluidisation
Cooling condition are as follows: powder material is cooled to room temperature ± 5 DEG C.
Present invention application skimmed milk power, the principal ingredients of whey powder, vegetable oil as Quinquagenarian formula milk powder, for stabilization
Property ingredient and heat-sensitive ingredients, the processing technology combined using wet-dry change, make the uniformity of milk powder finished product is high, instant effect is good,
Stability is more excellent, and proposes the formula of optimization.
Compared with traditional old milk powder, unsaturated fatty acid docosahexaenoic acid (DHA) and peanut that the present invention contains
Tetraenoic acid (AA) is essential fatty acid, respectively 6 fatty acid of ω and omega-3 fatty acid, clear in conjunction with linseed oil (ALA)
The ratio that omega-3 fatty acid and 6 fatty acid of ω are coordinated, has and reinforces memory function.
6 total fatty acid content 4.5-5.0g/kg of ω 3 and ω in this formula milk, wherein 6 content of fatty acid 2.5- of ω
4.0g/kg, ω 3 content of fatty acid 1.5-3.0g/kg, ω 6 fatty acid and 3 fatty acid proportion of ω 1.5:1 ~ 2.2:1 it
Between.
In conjunction in, compared with the background art, modification scenario ω -3 of the present invention and the serial fat ratio of ω -6 are determined preferably
Combination helps to assist memory function.
Detailed description of the invention
Fig. 1 be using micro-capsule carburetion compared with the milk powder form that conventional oil obtains figure.
Specific embodiment
Below with reference to test example and specific embodiment, the present invention is described in further detail.But this should not be understood
It is all that this is belonged to based on the technology that the content of present invention is realized for the scope of the above subject matter of the present invention is limited to the following embodiments
The range of invention.
Embodiment 1: one kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method
1) prepared by microcapsules carburetion
By following mass percent feeding: palm oil 80%, linseed oil 10%, concentration be 35~45% algae oil extract DHA5%,
The ARA grease 5% that concentration is 40~45%；
Using casein mixture as wall material, wherein beta-casein account for mass ratio be 70%, solid-liquid ratio 4:1, carry out emulsification pretreatment and
Homogeneous obtains microcapsules carburetion, wherein for emulsification pretreatment condition are as follows: temperature is kept for 45 ± 5 DEG C, and revolving speed sets 8000rpm operation
10min, processing condition are as follows: pressure 30Mpa.
2) newborn original washing powder preparation
Take 600 parts of pure water, be added 200 parts of skimmed milk powder, 80 parts of desalted whey powder, 30 parts of microcapsules carburetion mixed, mix
Stirring rate 1000rpm/min is closed, stirs 5~10min, progress is high-pressure homogeneous, and the pressure of homogeneous is set as 30Mpa；High pressure is equal
It is concentrated under reduced pressure after matter, reduced pressure condition is that temperature is kept for 55 ± 5 DEG C, and vacuum degree is set as 0.04Mpa, using two effects
It is 35% that falling film type, which is concentrated to dryness content of material,；Material after reduced pressure is pumped into storage container and is warming up to 65 DEG C, keeps the temperature 20 points
Clock, material in high-pressure pump pump-in pressure formula spray drying tower through being dried after reduced pressure, and temperature of charge is kept for 70 DEG C, air inlet
160 DEG C of temperature, 80 DEG C of leaving air temp, then in fluidized bed cooling, powder material is cooled to room temperature ± 5 DEG C, obtains newborn original washing powder.
3) it deploys
The newborn sealed Pipeline transport of original washing powder in the following proportions mixes newborn original washing powder with nutrient to mixing machine: newborn original washing powder 1000kg,
Galactooligosaccharide 0.5kg, taurine 0.5kg, L-carnitine-L-tartrate 0.5kg, ferrous lactate 0.5kg, beta carotene
0.5kg, zinc lactate 0.5kg, L-AA sodium 0.5kg, vitamin premix (including vitamin D, vitamin E, vitamin
K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, folic acid, pantothenic acid, biotin) 2kg is to get being rich in
DHA, AA and ALA Quinquagenarian formula milk powder.
6 total fatty acid content 5g/kg of ω 3 and ω in this formula milk, wherein 6 content of fatty acid 3.2g/kg, ω 3 of ω
6 fatty acid of content of fatty acid 1.8g/kg, ω and 3 fatty acid proportion 1.8:1 of ω.
The milk powder processed using the present embodiment micro-capsule carburetion and non-micro-capsule carburetion stored its shape by 3,4 and 8 hours
State is shown in attached drawing 1, by Fig. 1 it can be seen that the obtained milk powder uniformity of the present embodiment is high, stability is more excellent.
Embodiment 2: one kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method
1) prepared by microcapsules carburetion
By following mass percent feeding: palm oil 70%, linseed oil 12%, concentration be 35~45% algae oil extract DHA3%,
The ARA grease 15% that concentration is 40~45%；
Using casein mixture as wall material, wherein beta-casein account for mass ratio be 70%, solid-liquid ratio 4:1, carry out emulsification pretreatment and
Homogeneous obtains microcapsules carburetion, wherein for emulsification pretreatment condition are as follows: temperature is kept for 45 ± 5 DEG C, and revolving speed sets 8000rpm operation
15min, processing condition are as follows: pressure 40Mpa.
2) newborn original washing powder preparation
Take 700 parts of pure water, be added 300 parts of skimmed milk powder, 60 parts of desalted whey powder, 10 parts of microcapsules carburetion mixed, mix
Stirring rate 1000rpm/min is closed, stirs 10min, progress is high-pressure homogeneous, and the pressure of homogeneous is set as 40Mpa；After high-pressure homogeneous
It is concentrated under reduced pressure, reduced pressure condition is that temperature is kept for 55 ± 5 DEG C, and vacuum degree is set as 0.06Mpa, using two effect falling liquid films
It is 40% that formula, which is concentrated to dryness content of material,；Material after reduced pressure is pumped into storage container and is warming up to 70 DEG C, keeps the temperature 25 minutes,
Material in high-pressure pump pump-in pressure formula spray drying tower through being dried after reduced pressure, and temperature of charge is kept for 75 DEG C, air inlet temperature
160 DEG C of degree, 75 DEG C of leaving air temp, then in fluidized bed cooling, powder material is cooled to room temperature ± 5 DEG C, obtains newborn original washing powder.
3) it deploys
The newborn sealed Pipeline transport of original washing powder in the following proportions mixes newborn original washing powder with nutrient to mixing machine: newborn original washing powder 1000kg,
Galactooligosaccharide 1kg, taurine 1kg, L-carnitine-L-tartrate 1kg, ferrous lactate 1kg, beta carotene 1kg, zinc lactate
1kg, L-AA sodium 1kg, vitamin premix (including vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin
B2, vitamin B6, vitamin B12, niacin, folic acid, pantothenic acid, biotin) 3kg to get rich in DHA, AA and ALA person in middle and old age be formulated
Milk powder.
6 total fatty acid content 4.9g/kg of ω 3 and ω in this formula milk, wherein 6 content of fatty acid 4.0g/kg, ω of ω
3 content of fatty acid 1.9g/kg, ω 6 fatty acid and 3 fatty acid proportion of ω be 2.1:1.
Claims (10)
1. one kind is rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that comprise the following steps that:
1) pure water, skimmed milk powder, desalted whey powder and the mixing of microcapsules carburetion are taken, newborn original washing powder, institute are made using wet processing
The microcapsules carburetion stated is extracted DHA, ARA grease by palm oil, linseed oil, algae oil and is obtained by microencapsulation；
2) the newborn original washing powder for taking step 1) to obtain is dry-mixed with nutrient, obtains rich in DHA, AA and ALA Quinquagenarian formula milk powder.
2. as described in claim 1 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that institute
500~700 parts of pure water, 100~300 parts of skimmed milk powder, 60~100 parts of desalted whey powder and microcapsules are taken in the step 1) stated
10~40 parts of carburetion mixing.
3. as claimed in claim 1 or 2 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, feature exists
Microcapsules carburetion is made by the raw material of following mass percent by microencapsulation in the step 1): palm oil 70~
90%, the ARA grease 5 that the algae oil that linseed oil 2~12%, concentration are 35~45% extracts DHA2~5%, concentration is 40~45%~
15%。
4. as claimed in claim 1 or 2 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, feature exists
Wet processing specifically includes high-pressure homogeneous, reduced pressure, spray drying and fluidisation cooling in the step 1).
5. as claimed in claim 1 or 2 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, feature exists
Newborn original washing powder and nutrient are dry-mixed in the step 2) specifically: the newborn sealed Pipeline transport of original washing powder is to mixing machine, by following
Ratio mixes newborn original washing powder with nutrient: newborn original washing powder 1000kg, 0.5~1.0kg of galactooligosaccharide, 0.5~1.0kg of taurine,
0.5~1.0kg of L-carnitine-L-tartrate, 0.5~1.0kg of ferrous lactate, 0.5~1.0kg of beta carotene, zinc lactate 0.5
~1.0kg, L-AA 0.5~1.0kg of sodium, 2~3kg of vitamin premix.
6. as claimed in claim 1 or 2 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, feature exists
In the micro-encapsulation technology are as follows: using casein mixture as wall material, it is 70% that wherein beta-casein, which accounts for mass ratio, solid-liquid ratio
For 4:1, emulsification pretreatment and homogeneous are carried out, wherein for emulsification pretreatment condition are as follows: temperature is kept for 45 ± 5 DEG C, and revolving speed sets 8000rpm
Run 10~15min, processing condition are as follows: 25~40Mpa of pressure.
7. as claimed in claim 4 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that institute
The high-pressure homogeneous condition stated are as follows: 25~40Mpa of pressure.
8. as claimed in claim 4 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that institute
The reduced pressure condition stated are as follows: temperature is kept for 55 ± 5 DEG C, and vacuum degree is set as 0.03~0.06Mpa, dense using two effect falling film types
Being reduced to dry matter content is 35~40%, and the material after reduced pressure is pumped into storage container and is warming up to 60~75 DEG C, heat preservation 5~
25 minutes.
9. as claimed in claim 4 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that institute
The spray drying condition stated are as follows: temperature of charge is kept for 60~75 DEG C, 160 DEG C of inlet air temperature, 75~90 DEG C of leaving air temp.
10. as claimed in claim 4 a kind of rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method, it is characterised in that
The fluidisation cooling condition are as follows: powder material is cooled to room temperature ± 5 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910329778.XA CN110115295A (en) | 2019-04-23 | 2019-04-23 | One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910329778.XA CN110115295A (en) | 2019-04-23 | 2019-04-23 | One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110115295A true CN110115295A (en) | 2019-08-13 |
Family
ID=67521318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910329778.XA Pending CN110115295A (en) | 2019-04-23 | 2019-04-23 | One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110115295A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442066A (en) * | 2003-03-25 | 2003-09-17 | 汕头市金园区丹味食品发展中心 | Milk powder and its preparation method |
| CN101449830A (en) * | 2008-12-29 | 2009-06-10 | 山东龙力生物科技有限公司 | Mid-aged milk powder added with biostime and preparation method thereof |
| CN103262893A (en) * | 2013-06-13 | 2013-08-28 | 俞祖勋 | Formula milk powder capable of improving intelligence |
| CN103504025A (en) * | 2012-06-25 | 2014-01-15 | 浙江康恩贝健康产品有限公司 | Wet preparation process of infant formula milk powder |
| CN105230811A (en) * | 2015-11-11 | 2016-01-13 | 嘉必优生物工程（武汉）有限公司 | High oil whey powder containing polyunsaturated fatty acid fat |
| CN107593920A (en) * | 2017-10-28 | 2018-01-19 | 卜球 | A kind of formula milk and its production method for contributing to middle-aged and old sight protectios |
| CN107771961A (en) * | 2016-08-24 | 2018-03-09 | 嘉必优生物技术（武汉）股份有限公司 | Application of the high oily whey powder in dry process milk powder craft |
| CN108013136A (en) * | 2017-11-29 | 2018-05-11 | 上海晨冠乳业有限公司 | A kind of Milk powder for middle-aged and old people of multidimensional high calcium and preparation method thereof |
| CN108056170A (en) * | 2016-11-08 | 2018-05-22 | 扬州明成机械新技术研发服务有限公司 | A kind of Milk powder for middle-aged and old people and preparation method |
| CN108720021A (en) * | 2018-04-18 | 2018-11-02 | 湖北欣和生物科技有限公司 | DHA algal oil microscapsule powder and preparation method thereof |
-
2019
- 2019-04-23 CN CN201910329778.XA patent/CN110115295A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442066A (en) * | 2003-03-25 | 2003-09-17 | 汕头市金园区丹味食品发展中心 | Milk powder and its preparation method |
| CN101449830A (en) * | 2008-12-29 | 2009-06-10 | 山东龙力生物科技有限公司 | Mid-aged milk powder added with biostime and preparation method thereof |
| CN103504025A (en) * | 2012-06-25 | 2014-01-15 | 浙江康恩贝健康产品有限公司 | Wet preparation process of infant formula milk powder |
| CN103262893A (en) * | 2013-06-13 | 2013-08-28 | 俞祖勋 | Formula milk powder capable of improving intelligence |
| CN105230811A (en) * | 2015-11-11 | 2016-01-13 | 嘉必优生物工程（武汉）有限公司 | High oil whey powder containing polyunsaturated fatty acid fat |
| CN107771961A (en) * | 2016-08-24 | 2018-03-09 | 嘉必优生物技术（武汉）股份有限公司 | Application of the high oily whey powder in dry process milk powder craft |
| CN108056170A (en) * | 2016-11-08 | 2018-05-22 | 扬州明成机械新技术研发服务有限公司 | A kind of Milk powder for middle-aged and old people and preparation method |
| CN107593920A (en) * | 2017-10-28 | 2018-01-19 | 卜球 | A kind of formula milk and its production method for contributing to middle-aged and old sight protectios |
| CN108013136A (en) * | 2017-11-29 | 2018-05-11 | 上海晨冠乳业有限公司 | A kind of Milk powder for middle-aged and old people of multidimensional high calcium and preparation method thereof |
| CN108720021A (en) * | 2018-04-18 | 2018-11-02 | 湖北欣和生物科技有限公司 | DHA algal oil microscapsule powder and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 武建刚，等: "母乳化脂肪微胶囊化工艺的研究", 《食品与机械》 * |
| 熊华，等: "仿母乳奶油粉的营养功能特性和婴儿配方奶粉干法生产", 《中国乳品工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4851431A (en) | Physiologically active and nutritional composition | |
| AU2010277679B2 (en) | Nutritional composition for lactating women | |
| Gordon et al. | Fat excretion of premature infants: I. Effect on fecal fat of decreasing fat intake | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| CN108703364A (en) | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof | |
| RU2658979C2 (en) | Infant formulas comprising optimised amino acid profiles | |
| US7951844B2 (en) | Tranquilizer and functional food | |
| JP2012206943A (en) | Sleep-improving agent | |
| CN110115295A (en) | One kind being rich in DHA, AA and ALA Quinquagenarian formula milk powder preparation method | |
| JPS5832867B2 (en) | Eggs containing high concentrations of lysozyme and iodine | |
| JP7123341B2 (en) | PGC-1α biosynthesis promoter and slow-twitch fast-twitch inhibitor | |
| EP3389415A1 (en) | Nutritional compositions and infant formulas to promote myelination in the brain | |
| CA3221669A1 (en) | Probiotic and uses thereof | |
| JP7344661B2 (en) | Method for producing food composition | |
| JPS6049764A (en) | Food composition | |
| CN110236197A (en) | Sea cucumber intestine egg oil composition, sea cucumber intestine ovum oil soft capsule and preparation method thereof | |
| CN110292125A (en) | Egg and layer breeding and feed addictive rich in alpha-linolenic acid and DHA nutrient | |
| CN109601987A (en) | A kind of microcapsule powder, wet nurse's nutrient supplement food and preparation method thereof | |
| RU2202217C2 (en) | Composition for dragee production | |
| TWI568441B (en) | A lactobacillus reuteri gmnl-263 composition for controlling body weight and its use thereof | |
| CN108157662A (en) | A kind of Se-enriched egg and its production method | |
| JP4997514B2 (en) | Antihypertensive agent | |
| CN117481215A (en) | Special medical infant food | |
| Wahlang et al. | A review on examination of breast milk in Ayurveda and its physicochemical properties with its component | |
| JP2010037225A (en) | Body fat-reducing agent containing milk whey kefir as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190813 |
|
| RJ01 | Rejection of invention patent application after publication |